{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T03:12:38Z","timestamp":1773198758655,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T00:00:00Z","timestamp":1526947200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12876-018-0790-2","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T13:00:01Z","timestamp":1526994001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sustained efficacy following resolution of frequent heartburn with an over-the-counter regimen of esomeprazole 20\u00a0mg or placebo for 14\u00a0days: two randomized trials"],"prefix":"10.1186","volume":"18","author":[{"given":"David A.","family":"Peura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Le Moigne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Wassel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,22]]},"reference":[{"issue":"6","key":"790_CR1","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1136\/gutjnl-2012-304269","volume":"63","author":"HB El-Serag","year":"2014","unstructured":"El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871\u201380.","journal-title":"Gut"},{"key":"790_CR2","first-page":"CD002095","volume":"5","author":"KE Sigterman","year":"2013","unstructured":"Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;5:CD002095.","journal-title":"Cochrane Database Syst Rev"},{"key":"790_CR3","doi-asserted-by":"crossref","unstructured":"Hunt R, Quigley E, Abbas Z, Eliakim A, Emmanuel A, Goh KL, et al. Coping with common gastrointestinal symptoms in the community: a global perspective on heartburn, constipation, bloating, and abdominal pain\/discomfort May 2013. J Clin Gastroenterol. 2014;48(7):567\u201378.","DOI":"10.1097\/MCG.0000000000000141"},{"issue":"5","key":"790_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11096-015-0150-z","volume":"37","author":"HF Boardman","year":"2015","unstructured":"Boardman HF, Heeley G. The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors. Int J Clin Pharm. 2015;37(5):709\u201316.","journal-title":"Int J Clin Pharm"},{"key":"790_CR5","unstructured":"Nexium 24HR [product labeling]. Madison, NJ: Pfizer Consumer Healthcare; 2014."},{"issue":"4","key":"790_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3810\/pgm.2014.07.2781","volume":"126","author":"DA Peura","year":"2014","unstructured":"Peura DA, Traxler B, Kocun C, Lind T. Esomeprazole treatment of frequent heartburn: two randomized, double-blind, placebo-controlled trials. Postgrad Med. 2014;126(4):33\u201341.","journal-title":"Postgrad Med"},{"issue":"1","key":"790_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1365-2036.2006.03171.x","volume":"25","author":"NG Hunfeld","year":"2007","unstructured":"Hunfeld NG, Geus WP, Kuipers EJ. Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther. 2007;25(1):39\u201346.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"790_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/fampra\/cmu050","volume":"31","author":"P Haastrup","year":"2014","unstructured":"Haastrup P, Paulsen MS, Begtrup LM, Hansen JM, Jarbol DE. Strategies for discontinuation of proton pump inhibitors: a systematic review. Fam Pract. 2014;31(6):625\u201330.","journal-title":"Fam Pract"},{"issue":"4","key":"790_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3810\/pgm.2009.07.2019","volume":"121","author":"PR Kushner","year":"2009","unstructured":"Kushner PR, Snoddy AM, Gilderman L, Peura DA. Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies. Postgrad Med. 2009;121(4):67\u201375.","journal-title":"Postgrad Med"},{"issue":"6","key":"790_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/00325481.2016.1203236","volume":"128","author":"D Peura","year":"2016","unstructured":"Peura D, Le Moigne A, Pollack C, Nagy P, Lind T. A 14-day regimen of esomeprazole 20 mg\/day for frequent heartburn: durability of effects, symptomatic rebound, and treatment satisfaction. Postgrad Med. 2016;128(6):577\u201383.","journal-title":"Postgrad Med"},{"key":"790_CR11","doi-asserted-by":"crossref","unstructured":"Johnson DA, Le Moigne A, Li J, Pollack C, Nagy P. Analysis of clinical predictors of resolution of sleep disturbance related to frequent nighttime heartburn and acid regurgitation symptoms in individuals taking esomeprazole 20 mg or placebo. Clin Drug Investig. 2016;36(7):531\u20138.","DOI":"10.1007\/s40261-016-0398-7"},{"key":"790_CR12","doi-asserted-by":"crossref","unstructured":"Bardhan KD, Muller-Lissner S, Bigard MA, Bianchi PG, Ponce J, Hosie J, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. BMJ. 1999;318(7182):502\u20137.","DOI":"10.1136\/bmj.318.7182.502"},{"issue":"6","key":"790_CR13","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1023\/B:DDAS.0000034551.39324.c3","volume":"49","author":"J Ponce","year":"2004","unstructured":"Ponce J, Arguello L, Bastida G, Ponce M, Ortiz V, Garrigues V. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig Dis Sci. 2004;49(6):931\u20136.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"790_CR14","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","volume":"10","author":"JM Shin","year":"2008","unstructured":"Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528\u201334.","journal-title":"Curr Gastroenterol Rep"},{"issue":"9\u201310","key":"790_CR15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s002280000206","volume":"56","author":"M Hassan-Alin","year":"2000","unstructured":"Hassan-Alin M, Andersson T, Bredberg E, Rohss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol. 2000;56(9\u201310):665\u201370.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"790_CR16","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/0016-5085(95)90571-5","volume":"109","author":"K Gedda","year":"1995","unstructured":"Gedda K, Scott D, Besancon M, Lorentzon P, Sachs G. Turnover of the gastric H+,K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion. Gastroenterology. 1995;109(4):1134\u201341.","journal-title":"Gastroenterology"},{"issue":"2","key":"790_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/00912700122009953","volume":"41","author":"GM Ferron","year":"2001","unstructured":"Ferron GM, McKeand W, Mayer PR. Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. J Clin Pharmacol. 2001;41(2):149\u201356.","journal-title":"J Clin Pharmacol"},{"issue":"25","key":"790_CR18","doi-asserted-by":"crossref","first-page":"13681","DOI":"10.1016\/S0021-9258(17)38778-1","volume":"260","author":"B Wallmark","year":"1985","unstructured":"Wallmark B, Larsson H, Humble L. The relationship between gastric acid secretion and gastric H+,K+-ATPase activity. J Biol Chem. 1985;260(25):13681\u20134.","journal-title":"J Biol Chem"},{"issue":"1","key":"790_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/0006-291X(85)90573-X","volume":"126","author":"WB Im","year":"1985","unstructured":"Im WB, Blakeman DP, Davis JP. Irreversible inactivation of rat gastric (H+-K+)-ATPase in vivo by omeprazole. Biochem Biophys Res Commun. 1985;126(1):78\u201382.","journal-title":"Biochem Biophys Res Commun"},{"key":"790_CR20","doi-asserted-by":"crossref","unstructured":"Reimer C, Sondergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137(1):80\u20137.","DOI":"10.1053\/j.gastro.2009.03.058"},{"issue":"7","key":"790_CR21","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/ajg.2010.81","volume":"105","author":"A Niklasson","year":"2010","unstructured":"Niklasson A, Lindstrom L, Simren M, Lindberg G, Bjornsson E. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol. 2010;105(7):1531\u20137.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"790_CR22","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3109\/00365521.2010.537684","volume":"46","author":"P Juul-Hansen","year":"2011","unstructured":"Juul-Hansen P, Rydning A. Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy-negative reflux disease. Is rebound hypersecretion of acid a problem? Scand J Gastroenterol. 2011;46(4):398\u2013405.","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"790_CR23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3109\/00365521.2012.746395","volume":"48","author":"AB Lodrup","year":"2013","unstructured":"Lodrup AB, Reimer C, Bytzer P. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment. Scand J Gastroenterol. 2013;48(5):515\u201322.","journal-title":"Scand J Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-018-0790-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-018-0790-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-018-0790-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T19:15:31Z","timestamp":1693682131000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-018-0790-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,22]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["790"],"URL":"https:\/\/doi.org\/10.1186\/s12876-018-0790-2","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,22]]},"assertion":[{"value":"16 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent was obtained from all individual participants included in these studies, which were conducted in accordance with the Declaration of Helsinki.The informed consent form and study protocol for each study were approved by Alpha Independent Review Board (San Clemente, California, USA).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"DAP has served as a consultant for AstraZeneca, Pfizer, Takeda, and Horizon.AL is an employee of Pfizer Consumer Healthcare.HW is an employee of Pfizer Consumer Healthcare.CP is a former employee of Pfizer Consumer Healthcare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"69"}}